PARP1 and ovarian cancer: Interestingly, Hill et al. [66] evaluated patient-derived ovarian cancer organoids, and found that a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity, whereas a functional defect in replication fork protection correlated more strongly with carboplatin sensitivity.